ADAPT AF-DES

Name: ADAPT AF-DES: Antithrombotic Strategies Beyond 12 Months for Patients With AF Treated With Drug-Eluting-Stents
Uploaded: 2025-11-12T05:00:00+00:00
Description: This video brief features Dr. Jung-Sun Kim reporting from AHA 2025 in New Orleans. He highlights the rationale and design of the ADAPT AF-DES trial, which

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

OCEAN Trial at AHA 2025: Anticoagulation After AF Ablation in High-Risk Patients
OCEAN Trial at AHA 2025: Anticoagulation After AF Ablation in High-Risk Patients
Atrial Fibrillation
OCEAN Trial at AHA 2025: Anticoagulation After AF Ablation in High-Risk Patients
- Atul Verma, MD
Remote screening for asymptomatic AF shows modest benefit
Remote screening for asymptomatic AF shows modest benefit
ESC Congress 2025
Remote screening for asymptomatic AF shows modest benefit
Implications Associated With Integrating Both Real-World Data and Clinical Trial Data Into Clinical Practice: AF Considerations
Implications Associated With Integrating Both Real-World Data and Clinical Trial Data Into Clinical Practice: AF Considerations
MinuteCE®
Implications Associated With Integrating Both Real-World Data and Clinical Trial Data Into Clinical Practice: AF Considerations
1.00 program credit
- Valeria Caso, MD, PhD
1.00 program credit
Patient Case Study: Cancer-Associated Thrombosis
Patient Case Study: Cancer-Associated Thrombosis
MinuteCE®
Patient Case Study: Cancer-Associated Thrombosis
1.00 program credit
- Renato D. Lopes, MD, MHS, PhD
- Alexander T. Cohen, MD, MBBS
1.00 program credit

ADAPT AF-DES: Antithrombotic Strategies Beyond 12 Months for Patients With AF Treated With Drug-Eluting-Stents

Recommended

Title

Share on ReachMD